Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
about
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesA Practical Approach to Management of Chronic Hepatitis BNatural History and Clinical Consequences of Hepatitis B Virus InfectionKASL clinical practice guidelines: management of chronic hepatitis BFibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancerMolecular mechanisms underlying occult hepatitis B virus infection.Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection.Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study.Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.Chemotherapy-related reactivation of hepatitis B infection: updates in 2013.Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy.Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis.Asian-Pacific consensus statement on the management of chronic hepatitis B: an update.Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy.Hepatitis B reactivation and rituximab in the oncology practice.When treating cancer, please don't forget hepatitis B.Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapyProphylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-AnalysisLamivudine for chronic hepatitis B.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.Management of hepatitis B reactivation in patients receiving cancer chemotherapy.Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy.Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO).Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis.Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection.Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapyScreening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.Rituximab-related viral infections in lymphoma patients.Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy.Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experienceHepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy.Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation.Hepatitis B virus reactivation associated with anti-neoplastic therapy.Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations.Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable Predictors.Hepatitis B virus reactivation in a patient undergoing steroid-free chemotherapy.
P2860
Q24616084-9B60BDBA-CCE4-4655-9328-9F9C7C0434D4Q24810145-42AC0D7C-CFB0-4B58-AF36-FB13875DF135Q24810151-EEAF9C1A-61C4-4E3A-906E-F859F059DE45Q26752475-B80EE491-4CE7-4921-BA77-752529E1EE30Q27488403-EE541EFF-E3EA-4C8F-B647-E11308DC1A45Q27686923-9C95C772-2878-44DB-981D-DCBCAACAD46AQ33359545-9448DBBA-BC4F-429A-8059-F5C1B5E3765EQ33619636-D79A5D82-F88A-4D07-A947-4C6AF93187C7Q33825391-BF5ECB5B-A3C2-416A-97A6-266A3FF71A62Q34404991-5FF829E6-DD74-4C0B-95A3-9C8574300299Q34627978-09FCAC72-CA92-4284-A182-B774C0999E22Q34734311-518C6CFB-F19D-421A-BDDD-BCB9F647F197Q35072182-D47A59DC-D207-43C0-9E64-F13E68E664F8Q35152610-FF249F74-B57B-4C4C-9D81-EFBF083FC709Q35583718-D416187B-51FD-4B98-AF4F-4D069360097FQ35584210-250FD533-10CB-4B78-8BA6-D8683EAC5CACQ35597892-1B18B1E0-7788-4B04-82B5-4A5CF1C3320CQ35658261-CF9D5A64-53A5-4665-BCA9-81E40ABE546CQ35917357-2757AEA2-9B2A-42A3-AC18-3D8620D91332Q36135493-6888C15B-6ECC-4BD7-B12B-E5AA450BB7B5Q36153966-24E728D4-A573-4F7B-B238-2FEDEF88E51FQ36220459-8BC60D46-F88B-4DC9-B239-BB7DF97FAE4EQ36364001-32E632DC-0530-4A4A-9CCF-4B9F2307FD66Q36367268-B313ED74-0265-4451-B6CE-C54C71E8292CQ36581066-2BFADAAD-9189-4CEC-910C-FE47FE0C0246Q36597776-17FDA14A-33CE-429B-BAED-FE97BE9FD871Q36694864-E20AF933-98E7-4872-8CB2-E2A66AE288E4Q36752181-6F2E647E-8F44-4928-9890-F893FE5FC375Q36871718-4143CF87-E6C5-437A-9B15-A66D88A842A7Q37001173-1D39671C-A247-4470-91AC-2F8EC76A9310Q37065113-C43DA9AE-CB31-4BD7-8039-709A4B2F208BQ37205405-F270136C-1CF6-497F-8F3B-9FE302ED5D19Q37764963-36CEE7BE-5E4F-4DDA-B042-1AE6571E0996Q37883147-974D7B57-877B-4F11-9F5D-B34331734214Q37912229-A26BD8C3-518A-4FFA-B759-4C1E8C8DBF0CQ38047362-BC89A75D-4577-459E-810E-8F3B4BDCB595Q39051743-59BDCA75-8124-494D-A54D-8926A6A7045FQ40405411-51501090-C4C4-4518-84BC-0CA81D14348FQ40691267-1553BA69-E5E5-4079-BB27-B524C32D005FQ42031603-73289BE1-DAA3-475F-88F9-3640F9884B75
P2860
Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Primary prophylaxis with lamiv ...... ies treated with chemotherapy.
@en
Primary prophylaxis with lamiv ...... ies treated with chemotherapy.
@nl
type
label
Primary prophylaxis with lamiv ...... ies treated with chemotherapy.
@en
Primary prophylaxis with lamiv ...... ies treated with chemotherapy.
@nl
prefLabel
Primary prophylaxis with lamiv ...... ies treated with chemotherapy.
@en
Primary prophylaxis with lamiv ...... ies treated with chemotherapy.
@nl
P2093
P2860
P1476
Primary prophylaxis with lamiv ...... cies treated with chemotherapy
@en
P2093
P2860
P356
10.1046/J.1365-2141.2001.03099.X
P407
P577
2001-10-01T00:00:00Z